| Literature DB >> 27384431 |
Andrés Navarrete1,2,3, Dulce Momblán4, Raúl Almenara4, Antonio Lacy4.
Abstract
Gastrointestinal stromal tumors (GIST) represent 0.1-3 % of gastrointestinal malignancy. Surgery is the mainstay of treatment, but in high-risk tumors, imatinib can help to achieve better oncological outcomes. We present a rare case of a patient with gastric GIST with very aggressive evolution in a short period of time despite the use of neoadjuvant therapy with imatinib.Entities:
Keywords: GIST; Gastric; Imatinib
Mesh:
Substances:
Year: 2016 PMID: 27384431 DOI: 10.1007/s11605-016-3196-x
Source DB: PubMed Journal: J Gastrointest Surg ISSN: 1091-255X Impact factor: 3.452